Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in Incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE®) in human immunodeficiency virus type-1 seropositive subjects

Viral Immunology

Volumn 10, Issue 4, 1997, Pages 221-228

  Moss, Ronald B ^a   Giermakowska, Wieslawa ^a   Lanza, Paola ^a   Turner, John L ^b   Wallace, Mark R ^c   Jensen, Fred C ^a   Theofan, Georgia ^a   Richieri, Steven P ^a   Carlo, Dennis J ^a  

^a Orchestra Therapeutics Inc   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c Space and Naval Warfare Systems Center Pacific   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; FREUND ADJUVANT; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ANTIGEN;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; VIRUS IMMUNITY;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0031423803     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.1997.10.221     Document Type: Article

References (19)

1. Bass, H.Z., J.L. Fahey, P. Nishanian, R. Detels, W. Cumberland, M. Kemeny, and S. Plaeger. 1997. Relation of impaired lymphocyte proliferative function to other major human immunodeficiency virus type 1-induced immunological changes. Clin. Diagn. Lab. Immunol. 4:64-69.
2. Binley, J.M., P.J. Klasse, Y. Cao, I. Jones, M. Markowitz, D.D. Ho, and J.P. Moore. 1997. Differential regulation of the antibody responses to gag and env proteins of human immunodeficiency virus type 1. J. Virol. 71:2799-2809.
3. Choi, D.J., S. Dube, T.P. Spicer, H.B. Slade, F.C. Jensen, and B.J. Poiesz. 1997. Sequence Note: HIV type 1 isolate Z321, the strain used to make a therapeutic HIV type 1 immunogen, is intersubtype recombinant. AIDS Res. Hum. Retroviruses 13:357-361.
4. Ferrari, G., W. Humphrey, M.J. McElrath, J.L. Excler, A.M. Duliege, M.L. Clements, L.C. Corey, D.P. Bolognesi, and K.J. Weinhold. 1997. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc. Natl. Acad. Sci. USA 94:1396-1401.
5. Gao, F., L. Yue, S. Craig, C.L. Thornton, D.L. Robertson, F.E. McCutchan, J.A. Bradac, P.M. Sharp, and B.H. Hahn. 1994. Genetic variation of HIV Type 1 in four World Health Organization-sponsored vaccine evaluation sites: generation of functional envelope (glycoprotein 160) clones representative of sequence subtypes A, B, C, and E. AIDS Res. Hum. Retroviruses 10:1359-1368.
6. Getchell, J.P., D.R. Hicks, A. Srinivasan, J.L. Heath, D.A. York, M. Malonga, D.N. Forthal, J.M. Mann, and J.B. McCormick. 1987. Human immunodeficiency virus isolated from a serum sample collected in 1976 in Central Africa. J. Infect. Dis. 156:833-837.
7. Kitchen, A.D., G.F. Mann, J.F. Harrison, and A.J. Zuckerman. 1989. Effect of gamma irradiation on the human immunodeficiency virus and human coagulation proteins. Vox. Sang. 56:223-229.
8. Lanza, P., R.B. Moss, W. Giermakowska, R.B. Hancock, S.P. Richieri, G. Theofan, F.C. Jensen, P. Salk, and D.J. Carlo. 1998. The effect of dose and adjuvant on immunization with a whole killed gp120-depleted HIV-1 Immunogen in a murine model for prophylactic vaccination. Vaccine, in press.
9. Lederman, M., E. Connick, A. Landay, H. Kessler, D. Kuritzkes, M. St. Clair, B. Kotzin, L. Fox, M. Heath-Chiozzi, F. Rousseau, and J. Spritzler. 1997. Partial immune reconstitution after 12 weeks of HAART (AZT, 3TC, Ritonavir) preliminary results of ACTG 315. 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C., Abstract #LB13.
10. LoGrippo, G.A. 1960. Investigations of the use of beta-propiolactone in virus inactivation. Ann. NY Acad. Sci. 83:578-594.
11. Loomis-Price, L., M. Mitchell, R. Moss, and M. Robb. Vaccine-specific antibodies detected in HIV-infected volunteers post immunization with whole, inactivated HIV [abstract]. In: Program and abstract book of the Conference on Advances in AIDS Vaccine Development: Ninth Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS, Bethesda, Maryland, May 4-7, 1997.
12. Moss, R.B., S.P. Richieri, F. Ferre, A.E. Daigle, R. Trauger, G. Theofan, W. Giermakowska, P. Lanza, S. Brostoff, and D.J. Carlo. 1997. HIV-1-specific functional immune measurements as markers of disease progression. J. Biomed. Sci. 4:127-131.
13. Moss, R.B., R.J. Trauger, W.K. Giermakowska, J.L. Turner, M.R. Wallace, F.C. Jensen, S.P. Richieri, F. Ferre, A.E. Daigle, C. Duffy, G. Theofan, and D.J. Carlo. 1997. Effect of immunization with an inactivated gp120-depleted HIV-1 immunogen on β-chemokine and cytokine production in subjects with HIV-1 infection. J. Aquir. Immune Defic. Syndr. Hum. Retrovirol. 14:343-350.
14. Richieri, S.P., R. Bartholomew, R.C. Aloia, J. Savary, G.R. Holt, F. Ferrer, R. Musil, H.R. Tian, R. Trauger, F. Jensen, D.J. Carlo, R.Z. Maigetter, and C.P. Prior. 1997. Characterization of highly purified inactivated HIV-1 particles isolated by anion exchange chromatography. Vaccine, in press.
15. + T cell responses associated with control of viremia. Science 278:1447-1450.
16. Schooley, R.T., C. Spino, S. Chiu, V. DeGruttola, D.R. Kuritzkes, for the ACTG209 and ACTG214 Study Teams. 1997. Poor immunogenicity of HIV-1 envelope vaccines with alum or MF59 adjuvant in HIV-infected individuals: results of two randomized trials [abstract 756]. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C.
17. Trauger, R.J., F. Ferre, A.E. Daigle, F.C. Jensen, R.B. Moss, S.H. Mueller, S.P. Richieri, H.B. Slade, and D.J. Carlo. 1994. Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type-1 (HIV-1) Immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells. J. Infect. Dis. 169:1256-1264.
18. 3 CD4 T lymphocytes (AIDS Clinical Trial Group Protocol 137). J. Infect. Dis. 173:1336-1346.
19. Wahren, B., G. Bratt, C. Persson, B. Leven, J. Hinkula, G. Gilljam, S. Nordlund, L. Eriksson, F. Volvovitz, P.A. Brolidem, and E. Sandstrom. 1994. Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160. AIDS 7:220-229.